BCR-ABL kinase domain (KD) mutation is the major mechanism contributing to suboptimal response to tyrosine kinase inhibitors (TKI) in BCR-ABL-positive chronic myeloid leukemia (CML) patients. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.